Tata India Pharma & Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹1,208 Cr

Expense Ratio

0.69%

ISIN

INF277K019A3

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

28 Dec 2015

About this fund

Tata India Pharma & Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Tata Mutual Fund. This fund has been in existence for 8 years, 10 months and 25 days, having been launched on 28-Dec-15.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹33.95, Assets Under Management (AUM) of 1208.05 Crores, and an expense ratio of 0.69%.

Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 14.72% since inception.
The fund's asset allocation comprises around 94.62% in equities, 0.00% in debts, and 5.38% in cash & cash equivalents.
You can start investing in Tata India Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+39.67%

+41.83% (Cat Avg.)

3 Years

+21.07%

+18.69% (Cat Avg.)

5 Years

+28.06%

+27.15% (Cat Avg.)

Since Inception

+14.72%

— (Cat Avg.)

Portfolio Summaryas of 31st October 2024

Equity	₹1,143.05 Cr	94.62%
Others	₹64.99 Cr	5.38%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹148.71 Cr	12.31%
Aurobindo Pharma Ltd	Equity	₹103.48 Cr	8.57%
Lupin Ltd	Equity	₹89.72 Cr	7.43%
Dr Reddy's Laboratories Ltd	Equity	₹78.31 Cr	6.48%
Cipla Ltd	Equity	₹76.04 Cr	6.29%
Cash / Net Current Asset	Cash	₹63.1 Cr	5.22%
Divi's Laboratories Ltd	Equity	₹61.82 Cr	5.12%
Fortis Healthcare Ltd	Equity	₹53.42 Cr	4.42%
Zydus Lifesciences Ltd	Equity	₹47.19 Cr	3.91%
Alkem Laboratories Ltd	Equity	₹43.49 Cr	3.60%
Apollo Hospitals Enterprise Ltd	Equity	₹41.37 Cr	3.42%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹29.21 Cr	2.42%
Ajanta Pharma Ltd	Equity	₹29.03 Cr	2.40%
Medi Assist Healthcare Services Ltd	Equity	₹25.85 Cr	2.14%
FDC Ltd	Equity	₹25.76 Cr	2.13%
Orchid Pharma Ltd	Equity	₹25.51 Cr	2.11%
HealthCare Global Enterprises Ltd	Equity	₹25.47 Cr	2.11%
Wockhardt Ltd	Equity	₹23.37 Cr	1.93%
Torrent Pharmaceuticals Ltd	Equity	₹22.71 Cr	1.88%
Ipca Laboratories Ltd	Equity	₹22.63 Cr	1.87%
Indoco Remedies Ltd	Equity	₹20.7 Cr	1.71%
Akums Drugs and Pharmaceuticals Ltd	Equity	₹16.11 Cr	1.33%
Piramal Pharma Ltd	Equity	₹16.02 Cr	1.33%
Jupiter Life Line Hospitals Ltd	Equity	₹14.31 Cr	1.18%
Sanofi India Ltd	Equity	₹13.02 Cr	1.08%
Laurus Labs Ltd	Equity	₹12.53 Cr	1.04%
Mankind Pharma Ltd	Equity	₹11.06 Cr	0.92%
Coromandel International Ltd	Equity	₹10.01 Cr	0.83%
Ami Organics Ltd	Equity	₹9.89 Cr	0.82%
Sanofi Consumer Healthcare India Ltd	Equity	₹9.44 Cr	0.78%
Syngene International Ltd	Equity	₹9.21 Cr	0.76%
Procter & Gamble Health Ltd	Equity	₹8.37 Cr	0.69%
Medplus Health Services Ltd	Equity	₹7.92 Cr	0.66%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹6.67 Cr	0.55%
Deepak Nitrite Ltd	Equity	₹4.72 Cr	0.39%
A) Repo	Cash - Repurchase Agreement	₹1.89 Cr	0.16%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹1,118.43 Cr	92.58%
Basic Materials	₹24.62 Cr	2.04%

Risk & Performance Ratios

Fund Managers

Meeta Shetty

Since March 2021

Rajat Srivastava

Since September 2024

Additional Scheme Detailsas of 31st October 2024

ISIN

INF277K019A3

Expense Ratio

0.69%

Exit Load

No Charges

Fund Size

₹1,208 Cr

Age

8 years 10 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

Nifty Pharma TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹28.64 Cr	43.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹881.52 Cr	37.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹881.52 Cr	35.4%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹40.84 Cr	37.9%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹208.21 Cr	45.8%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹208.21 Cr	43.1%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2770.21 Cr	38.2%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2770.21 Cr	36.2%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹852.28 Cr	36.6%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹19.81 Cr	37.0%

About the AMC

Tata Mutual Fund

+91 22 6657 8282

https://www.tatamutualfund.com/

Total AUM

₹1,85,301 Cr

Address

Mafatlal Centre, 9th Floor, Mumbai, 400 021

Other Funds by Tata Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Tata Silver ETF Fund of Fund Direct Growth Very High Risk	0.1%	0.0%	₹72.09 Cr	-
Tata Gold ETF Fund of Fund Direct Growth High Risk	0.2%	0.0%	₹117.15 Cr	-
Tata Fixed Maturity Plan Series 56 Scheme G Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Fixed Maturity Plan Series 56 Scheme H Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Fixed Maturity Series E Direct Growth Low to Moderate Risk	-	0.0%	-	-
Tata Balanced Advantage Fund Direct Growth High Risk	0.4%	1.0%	₹10288.08 Cr	17.4%
Tata Ultra Short Term Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹3362.75 Cr	7.8%
Tata Business Cycle Fund Direct Growth Very High Risk	0.5%	1.0%	₹2885.41 Cr	28.3%
Tata Nifty India Digital ETF Fund of Fund Direct Growth Very High Risk	0.1%	1.0%	₹86.29 Cr	32.0%
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹854.56 Cr	8.7%
Tata Floating Rate Fund Direct Growth Moderate Risk	0.3%	0.0%	₹145.81 Cr	8.1%
Tata Small Cap Fund Direct Growth Very High Risk	0.3%	1.0%	₹9463.78 Cr	35.9%
Tata Large & Mid Cap Fund Direct Growth Very High Risk	0.6%	1.0%	₹8390.40 Cr	24.5%
Tata Mid Cap Growth Fund Direct Growth Very High Risk	0.7%	1.0%	₹4443.96 Cr	29.6%
Tata Hybrid Equity Fund Direct Growth Very High Risk	1.0%	1.0%	₹4137.30 Cr	20.9%
Tata Ethical Fund Direct Growth Very High Risk	0.7%	0.0%	₹3201.55 Cr	23.1%
Tata Gilt Securities Fund Direct Growth Moderate Risk	0.3%	0.0%	₹873.66 Cr	9.8%
Tata Equity P/E Fund Direct Growth Very High Risk	0.8%	1.0%	₹8681.31 Cr	33.5%
Tata Infrastructure Fund Direct Growth Very High Risk	1.1%	0.0%	₹2451.22 Cr	33.6%
Tata Treasury Advantage Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹2587.66 Cr	7.9%
Tata Money Market Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹26782.99 Cr	8.0%
Tata Equity Savings Fund Direct Growth Moderate Risk	0.5%	0.0%	₹215.99 Cr	15.2%
Tata Young Citizens Fund Direct Growth Very High Risk	1.9%	1.0%	₹367.04 Cr	18.6%
Tata Liquid Fund Direct Growth Moderate Risk	0.2%	0.0%	₹23832.34 Cr	7.5%
Tata Large Cap Fund Direct Growth Very High Risk	1.0%	1.0%	₹2415.27 Cr	24.3%
Tata Retirement Savings Moderate Fund Direct Growth Very High Risk	0.6%	1.0%	₹2161.97 Cr	23.2%
Tata Retirement Savings Conservative Fund Direct Growth Moderately High risk	1.0%	1.0%	₹174.39 Cr	12.4%
Tata Short Term Bond Fund Direct Growth Moderate Risk	0.4%	0.0%	₹2904.29 Cr	8.4%
Tata Retirement Savings Progressive Fund Direct Growth Very High Risk	0.5%	1.0%	₹2088.63 Cr	25.2%
Tata Corporate Bond Fund Direct Growth Moderate Risk	0.3%	0.0%	₹2771.11 Cr	8.9%
Tata India Consumer Fund Direct Growth Very High Risk	0.7%	0.0%	₹2374.84 Cr	29.9%
Tata Digital India Fund Direct Growth Very High Risk	0.4%	0.0%	₹11835.20 Cr	38.2%
Tata Banking & Financial Services Fund Direct Growth Very High Risk	0.5%	0.0%	₹2374.28 Cr	18.4%
Tata Resources & Energy Fund Direct Growth Very High Risk	0.6%	0.0%	₹1042.41 Cr	28.1%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1208.05 Cr	39.7%
TATA Nifty G-SEC Dec 2029 Index Fund Direct Growth Moderate Risk	0.1%	0.0%	₹178.27 Cr	9.2%
Tata Multi Asset Opportunities Fund Direct Growth Very High Risk	0.5%	1.0%	₹3409.99 Cr	22.7%
Tata Flexi Cap Fund Direct Growth Very High Risk	0.7%	1.0%	₹3008.93 Cr	21.8%
Tata Dividend Yield Fund Direct Growth Very High Risk	0.7%	1.0%	₹994.96 Cr	23.1%
Tata Housing Opportunities Fund Direct Growth Very High Risk	0.7%	1.0%	₹609.92 Cr	19.4%
Tata Arbitrage Fund Direct Growth Low Risk	0.3%	0.0%	₹12432.45 Cr	8.5%
Tata Banking & PSU Debt Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹207.53 Cr	7.0%
Tata Overnight Fund Direct Growth Low Risk	0.1%	0.0%	₹4311.01 Cr	6.8%
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹632.70 Cr	37.4%
Tata CRISIL IBX Gilt Index-April 2026 Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹1069.63 Cr	7.9%
Tata Multicap Fund Direct Growth Very High Risk	0.5%	1.0%	₹3218.66 Cr	19.4%
Tata Treasury Advantage Fund Segregated Portfolio 1 Direct Growth Low to Moderate Risk	-	0.0%	-	154.6%
Tata Medium Term Fund Segregated Portfolio 1 Direct Growth Moderate Risk	-	1.0%	-	187.2%
Tata Corporate Bond Fund Segregated Portfolio 1 Direct Growth Moderate Risk	-	0.0%	-	116.5%
TATA Nifty G-Sec Dec 2026 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹107.77 Cr	8.1%

Risk Level

Your principal amount will be at Very High Risk

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

What is the current NAV of Tata India Pharma & Healthcare Fund Direct Growth?

The NAV of Tata India Pharma & Healthcare Fund Direct Growth, as of 21-Nov-2024, is ₹33.95.

What are the returns of Tata India Pharma & Healthcare Fund Direct Growth?

The fund has generated 39.67% over the last 1 year and 21.07% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Tata India Pharma & Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 94.62% in equities, 0.00% in bonds, and 5.38% in cash and cash equivalents.

Who manages the Tata India Pharma & Healthcare Fund Direct Growth?

The fund managers responsible for Tata India Pharma & Healthcare Fund Direct Growth are:-

Meeta Shetty
Rajat Srivastava

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Our weekly expert newsletter on stories that matter to your money.

Knowledge Repository

Bonds

IPA

Mutual Funds

Portfolio Management Services

About

Investment Philosophy

Legal

Returns & Cancellation

Security

Terms & Disclosure

KYC Check

©2021-2024 Dezerv. All Rights Reserved

Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

Tata India Pharma & Healthcare Fund Direct Growth

Fund Overview